跳至主要内容
临床试验/NCT05392374
NCT05392374No Longer Available不适用

Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

Chimerix10 个研究点 分布在 1 个国家开始时间: 2022年5月26日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
No Longer Available
发起方
Chimerix
试验地点
10

研究概览

简要总结

This is an intermediate-size expanded access protocol to provide ONC201 to patients with diffuse intrinsic pontine gliomas who cannot access ONC201 through clinical trials.

研究设计

研究类型
Expanded Access

入排标准

年龄范围
6 Months 至 18 Years(Child, Adult)
接受健康志愿者

入选标准

  • Patient with DIPG who failed at least one line of prior therapy such as focal radiation therapy
  • Patient must be > than 6 months and < 18 years of age.
  • Confirmed evidence of disease progression from immediately prior therapy or refractory to the immediately prior treatment.
  • Karnofsky/Lansky performance status ≥
  • Adequate organ and marrow function as defined below:
  • Absolute neutrophil count ≥1,000/mm3 without growth factor use ≤ 7 days prior to treatment (cycle 1 day 1, C1D1)
  • ________________________________________________________________________________ CONFIDENTIAL Page 3 of 45
  • Hemoglobin>8.0 mg/dL without red blood cell transfusion ≤ 3 days prior to C1D1
  • Total serum bilirubin<1.5 X upper limit of normal (ULN)
  • AST (SGOT)/ALT (SGPT)≤2 X ULN;; ≤ 5 X ULN if there is liver involvement secondary to tumor
  • Serum creatinine≤ 1.5 X ULN (OR creatinine clearance ≥ 60 mL/min/1.73 m2)
  • Ability to understand and the willingness to sign a written informed consent document by the patient or their legal guardian.
  • If patient is of child--bearing age, female patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. Male patients must be surgically sterile or must agree to use effective contraception during the period of the trial and for at least 90 days after completion of treatment. The decision of effective contraception will be based on the judgment of the principal investigator or a designated associate.
  • Patient must be able to swallow capsules and retain orally administered medication.

排除标准

  • Body weight >10Kg.
  • Known active bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV).
  • Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)--related illness.
  • Active or prior plasma cell leukemia (defined as either 20% of peripheral WBC comprised of plasma/CD138+ cells or an absolute count of 2 x 10^9/L).
  • Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia.
  • Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack or symptomatic pulmonary embolism.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, or in the judgment of the investigator would make the patient inappropriate for entry into the study.

研究者

发起方
Chimerix
申办方类型
Industry
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验